Core Viewpoint - Silver诺医药 successfully listed on the Hong Kong Stock Exchange, becoming another 18A biotech company, with a highly oversubscribed IPO of 5,364 times, surpassing the previous record of 5,200 times by Mixue Group [1] Group 1: IPO Details - The IPO price was set at HKD 18.68 per share, resulting in a market capitalization exceeding HKD 8.5 billion [1] - The total funds raised amounted to HKD 683 million, with a net amount of HKD 610 million after deducting issuance costs [1] - Approximately 90% of the net proceeds will be allocated to ongoing and planned clinical trials and the commercialization of the core product, Isu-Paglutide a, while about 10% will be used for operational funds and general corporate purposes [1] Group 2: Company Overview - Founded in 2014, Silver诺医药 focuses on discovering, developing, and commercializing innovative therapies for diabetes and other metabolic diseases [1] - The company has established a pipeline of candidate drugs targeting diabetes and other metabolic diseases, including the core product Isu-Paglutide a for treating obesity and metabolic dysfunction-related fatty liver disease (MASH), along with five preclinical candidates [1] Group 3: Core Product Information - Isu-Paglutide a is a human long-acting GLP-1 receptor agonist approved in China for treating type 2 diabetes (T2D) [2] - Phase III clinical data shows that patients treated with 3.0 mg of Isu-Paglutide a can reduce HbA1c levels by 1.1% within the first four weeks, and by 2.2% after 24 weeks, comparable to a reduction of 1.8% when combined with Metformin [2] - The drug demonstrates a 60% diabetes remission rate three months after discontinuation in newly diagnosed T2D patients, indicating sustained efficacy [2] - Silver诺医药 plans to commercialize Isu-Paglutide a in China by February 2025, initially collaborating with CDMO partners for production before establishing its own facilities to enhance internal production capacity [2]
认购5364倍超蜜雪集团 银诺医药今天在港上市